Interneuron Pharma's First Quarter
Interneuron Pharmaceuticals of the USA achieved revenues of $17.7million in the quarter ended December 31, 1996, up from $5.3 million in the like, year-earlier period. "Redux (dexfenfluramine)-related revenue in Interneuron's first quarter of fiscal 1997 reflects strong early sales of the product," commented Glenn Cooper, president and chief executive of the firm.
The company reported a net loss of $2.9 million, or 7 cents per share in the 1996 three-month period, compared with $3.2 million, or 9 cents per share a year earlier.
Mr Cooper commented: "clinical activity during the quarter included the beginning of the first pivotal Phase II/III trial of pagoclone in patients suffering from panic disorder."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze